See more : Lianhe Chemical Technology Co., Ltd. (002250.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Akebia Therapeutics, Inc. (AKBA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akebia Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- IMINT Image Intelligence AB (publ.) (IMNTF) Income Statement Analysis – Financial Results
- Manhattan Associates, Inc. (MANH) Income Statement Analysis – Financial Results
- Nations Royalty Corp. (NRC.V) Income Statement Analysis – Financial Results
- SBM Offshore N.V. (SBMO.AS) Income Statement Analysis – Financial Results
- Roche Holding AG (RHHVF) Income Statement Analysis – Financial Results
Akebia Therapeutics, Inc. (AKBA)
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.62M | 292.60M | 213.58M | 295.31M | 335.00M | 207.74M | 177.98M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 74.15M | 84.80M | 153.39M | 295.91M | 145.34M | 7.69M | 617.00K | 115.79M | 96.00K | 23.26M | 0.00 | 0.00 |
| Gross Profit | 120.47M | 207.81M | 60.18M | -601.00K | 189.67M | 200.06M | 177.37M | -114.25M | -96.00K | -23.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 61.90% | 71.02% | 28.18% | -0.20% | 56.62% | 96.30% | 99.65% | -7,443.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 63.08M | 129.11M | 147.85M | 218.49M | 322.97M | 291.07M | 230.89M | 115.79M | 43.02M | 25.40M | 10.78M | 5.63M |
| General & Administrative | 0.00 | 141.87M | 177.65M | 157.36M | 152.98M | 87.13M | 27.01M | 22.21M | 18.50M | 12.54M | 5.15M | 2.89M |
| Selling & Marketing | 100.23M | -3.18M | 174.16M | 153.95M | 149.46M | 87.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.23M | 141.87M | 174.16M | 153.95M | 149.46M | 87.06M | 27.01M | 22.21M | 18.50M | 12.54M | 5.15M | 2.89M |
| Other Expenses | 3.42M | -12.54M | 3.49M | 3.41M | 3.53M | 6.24M | 204.00K | -188.00K | 287.00K | 700.00K | 1.05M | 1.97M |
| Operating Expenses | 166.73M | 270.99M | 325.50M | 375.84M | 475.95M | 378.20M | 257.90M | 138.00M | 61.51M | 37.94M | 15.93M | 8.52M |
| Cost & Expenses | 240.88M | 355.78M | 478.90M | 671.75M | 621.29M | 385.88M | 257.90M | 138.00M | 61.51M | 37.94M | 15.93M | 8.52M |
| Interest Income | 0.00 | 15.69M | 19.95M | 8.92M | 2.19M | 6.15M | 2.80M | 901.00K | 0.00 | 0.00 | 0.00 | 1.64M |
| Interest Expense | 6.03M | 15.69M | 19.94M | 8.87M | 1.40M | 6.15M | 0.00 | 0.00 | 510.00K | 206.00K | 703.57K | 0.00 |
| Depreciation & Amortization | 37.63M | 35.28M | 36.13M | 33.59M | 36.42M | 2.42M | 617.00K | 296.00K | 96.00K | 49.00K | 1.28K | 39.16K |
| EBITDA | -6.87M | -43.26M | -225.96M | -341.00M | -247.64M | -178.09M | -76.06M | -136.16M | -61.42M | -37.89M | -12.46M | -6.55M |
| EBITDA Ratio | -3.53% | -15.84% | -124.23% | -127.47% | -85.46% | -85.75% | -44.55% | -8,870.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.26M | -63.18M | -265.32M | -376.44M | -286.29M | -178.14M | -79.92M | -136.46M | -61.51M | -37.94M | -15.93M | -8.52M |
| Operating Income Ratio | -23.77% | -21.59% | -124.23% | -127.47% | -85.46% | -85.75% | -44.90% | -8,889.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.67M | -13.45M | -17.52M | -5.63M | -2.00K | 6.24M | 3.00M | 713.00K | 497.00K | 906.00K | 2.77M | 327.00K |
| Income Before Tax | -51.93M | -92.56M | -282.84M | -383.46M | -286.29M | -171.90M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.20M |
| Income Before Tax Ratio | -26.68% | -31.63% | -132.43% | -129.85% | -85.46% | -82.75% | -43.21% | -8,843.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.45M | -37.97M | -33.59M | -6.63M | -28.34M | -2.80M | -901.00K | -510.00K | -206.00K | 1.75M | 1.60M |
| Net Income | -51.93M | -106.01M | -244.87M | -349.87M | -279.66M | -171.90M | -76.91M | -135.75M | -60.72M | -37.03M | -13.17M | -8.20M |
| Net Income Ratio | -26.68% | -36.23% | -114.65% | -118.48% | -83.48% | -82.75% | -43.21% | -8,843.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 | -0.81 |
| EPS Diluted | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 | -1.77 | -3.60 | -2.29 | -2.40 | -0.68 | -0.81 |
| Weighted Avg Shares Out | 187.47M | 182.78M | 165.95M | 138.46M | 118.40M | 116.89M | 43.50M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
| Weighted Avg Shares Out (Dil) | 187.47M | 182.78M | 165.95M | 138.46M | 118.40M | 116.89M | 43.50M | 37.72M | 26.47M | 15.41M | 19.27M | 10.13M |
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Akebia Therapeutics: Waiting For Round 2
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Source: https://incomestatements.info
Category: Stock Reports